[go: up one dir, main page]

AU2001257521A1 - Prostaglandin compounds for treating congestive heart failure - Google Patents

Prostaglandin compounds for treating congestive heart failure

Info

Publication number
AU2001257521A1
AU2001257521A1 AU2001257521A AU5752101A AU2001257521A1 AU 2001257521 A1 AU2001257521 A1 AU 2001257521A1 AU 2001257521 A AU2001257521 A AU 2001257521A AU 5752101 A AU5752101 A AU 5752101A AU 2001257521 A1 AU2001257521 A1 AU 2001257521A1
Authority
AU
Australia
Prior art keywords
heart failure
congestive heart
treating congestive
prostaglandin compounds
prostaglandin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001257521A
Inventor
Michael Bentley
Martine Rothblatt
Robert Shorr
Xuan Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Therapeutics Corp
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Publication of AU2001257521A1 publication Critical patent/AU2001257521A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2001257521A 2000-06-05 2001-05-03 Prostaglandin compounds for treating congestive heart failure Abandoned AU2001257521A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09587458 2000-06-05
US09/587,458 US6242482B1 (en) 2000-06-05 2000-06-05 Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
PCT/US2001/014338 WO2001093862A1 (en) 2000-06-05 2001-05-03 Prostaglandin compounds for treating congestive heart failure

Publications (1)

Publication Number Publication Date
AU2001257521A1 true AU2001257521A1 (en) 2001-12-17

Family

ID=24349885

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001257521A Abandoned AU2001257521A1 (en) 2000-06-05 2001-05-03 Prostaglandin compounds for treating congestive heart failure

Country Status (8)

Country Link
US (1) US6242482B1 (en)
EP (1) EP1299096A1 (en)
JP (1) JP2003535132A (en)
KR (1) KR20030038547A (en)
CN (1) CN1433307A (en)
AU (1) AU2001257521A1 (en)
CA (1) CA2408542A1 (en)
WO (1) WO2001093862A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803386B2 (en) 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
DE10209822A1 (en) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of low molecular weight substances to a modified polysaccharide
DE10209821A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of proteins to a modified polysaccharide
ES2622471T5 (en) 2003-05-22 2020-07-23 United Therapeutics Corp Compounds and procedures for the administration of prostacyclin analogs
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
WO2006014930A2 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US20070014784A1 (en) * 2005-06-23 2007-01-18 Medtronic Vascular, Inc. Methods and Systems for Treating Injured Cardiac Tissue
KR101390579B1 (en) 2006-05-15 2014-05-19 유나이티드 세러퓨틱스 코오포레이션 Treprostinil administration using a metered dose inhaler
US10213464B2 (en) * 2011-01-13 2019-02-26 Scipharm Sarl Method for enhancing engraftment of haematopoetic stem cells
US9872864B2 (en) * 2011-08-12 2018-01-23 Ascendis Pharma A/S Sustained release composition of prostacyclin
EP2674413B1 (en) * 2012-06-15 2017-06-07 SciPharm SàRL Process for the preparation of treprostinil and derivatives thereof
AU2013353985B2 (en) * 2012-12-07 2017-07-13 Ascendis Pharma A/S Carrier-linked prostanoid prodrugs
JP6542128B2 (en) * 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド Treprostinil Prodrugs
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9758465B2 (en) 2013-04-30 2017-09-12 United Therapeutics Corporation Controlled release pharmaceutical formulations
SI3060041T1 (en) 2013-10-25 2021-04-30 Insmed Incorporated Prostacyclin compounds
WO2016010538A1 (en) * 2014-07-16 2016-01-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
AU2015349969B2 (en) 2014-11-18 2020-02-06 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) * 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
JP2019519489A (en) 2016-05-05 2019-07-11 リクイディア・テクノロジーズ・インコーポレーテッド Dry powder Treprostinil for treating pulmonary hypertension
WO2020072982A1 (en) 2018-10-05 2020-04-09 Xenotherapeutics, Inc. Xenotransplantation products and methods
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
CN114072136B (en) 2019-04-29 2024-11-29 英斯梅德股份有限公司 Dry powder compositions of treprostinil prodrugs and methods of use thereof
JP2020011957A (en) * 2019-07-22 2020-01-23 コルセア ファーマ インコーポレイテッド Treprostinil derivative compound and method of using the same
WO2021211916A1 (en) 2020-04-17 2021-10-21 United Therapeutics Corporation Treprostinil for use in the treatment of intersitial lung disease
JP7138685B2 (en) * 2020-10-26 2022-09-16 コルセア ファーマ インコーポレイテッド Treprostinil derivative compounds and methods of use thereof
USD1037201S1 (en) * 2022-05-25 2024-07-30 Razer (Asia Pacific) Pte. Ltd. Headphone

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO2000057701A1 (en) 1999-03-31 2000-10-05 United Therapeutics Corporation Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension

Also Published As

Publication number Publication date
EP1299096A1 (en) 2003-04-09
CN1433307A (en) 2003-07-30
WO2001093862A1 (en) 2001-12-13
JP2003535132A (en) 2003-11-25
KR20030038547A (en) 2003-05-16
CA2408542A1 (en) 2001-12-13
US6242482B1 (en) 2001-06-05

Similar Documents

Publication Publication Date Title
AU2001257521A1 (en) Prostaglandin compounds for treating congestive heart failure
AU2879299A (en) Controlling congestive heart failure
AU2003214214A1 (en) Method for treating congestive heart failure
AU2002221239A1 (en) Therapeutic benzimidazole compounds
AU2001284483A1 (en) Remedies for heart failure
AUPQ253199A0 (en) Non-prostanoid prostaglandin I2-agonist
AU5690900A (en) Process for oxidising aromatic compounds
AUPR878201A0 (en) New compounds
MXPA03008205A (en) Process for the preparation of imidazole compounds.
AU2002320098A1 (en) Dye-azide compounds for dual phototherapy
AU5935600A (en) Phosphoramide compounds
AU2002225724A1 (en) Motilide compounds
AU2002218171A1 (en) Method for producing aryl compounds
AU2002214954A1 (en) Process for the preparation of phenylphenol compounds
AU1950899A (en) Compounds for increased bioavailability
AU5887400A (en) Derivative compounds
AU6870600A (en) Process for the preparation of 2,3-dihydroazepine compounds
AU3324700A (en) Imidazole compounds
AU4578501A (en) Method for treating congestive heart failure
AUPQ515700A0 (en) Imidazole compounds
AU2001256278A1 (en) Use of cse inhibitors for treating heart failure
AU2001235423A1 (en) Method for producing 2,3,5,6-tetrahalogen-xylylidene compounds
AU2002351560A1 (en) Treatment of congestive heart failure
AU2001276370A1 (en) Process for the preparation of pesticidal compounds
AU2002216043A1 (en) Compounds